What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2022.2152321
Abstract: ABSTRACT Introduction Psoriatic arthritis (PsA) is a chronic arthritis typically associated with cutaneous psoriasis (PsO). Its pathogenesis is connected to an innate and acquired immune response, as well as genetic risk alleles. The extent of… read more here.
Keywords: next biological; psoriatic arthritis; biological targeted; targeted synthetic ... See more keywords
Advances in biological and targeted therapies for systemic sclerosis
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2023.2196009
Abstract: ABSTRACT Introduction Systemic sclerosis (SSc) is a severe, and often life-threatening, autoimmune disease, which causes inflammation and fibrosis of the skin and internal organs. There are currently limited effective therapeutic options for patients with SSc.… read more here.
Keywords: systemic sclerosis; advances biological; ssc; biological targeted ... See more keywords
Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.
Sign Up to like & getrecommendations! Published in 2023 at "Modern rheumatology"
DOI: 10.1093/mr/road031
Abstract: OBJECTIVE We compared the incidence rates of hospitalized infections (HIs) between tocilizumab (TCZ) and other biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in adults aged ≥75 years with rheumatoid arthritis (RA). METHODS We used a Japanese claims… read more here.
Keywords: synthetic disease; risk; hospitalized infections; biological targeted ... See more keywords